These data suggest that the tumor cell-intrinsic differences between BRCA1 and BRCA2 deficiency result in differences in immune landscapes, immune cell infiltration of tumors and distinct resistance mechanisms, and require further investigation for the future clinical trials design. This evidence concerns the gene BRCA1 and neoplasm.